April 20th, 2012
Aliskiren (Tekturna) Gets New Warning and Contraindication from FDA
Larry Husten, PHD
The FDA has issued new warnings about antihypertensive drugs containing the direct renin inhibitor aliskiren (including Tekturna, Amturnide, Takamio, and Valturna) when used in combination with ACE inhibitors or angiotensin-receptor blockers (ARBs). The FDA now states that these drug combinations are contraindicated in patients with diabetes, and it is adding a new warning to avoid […]
December 20th, 2011
ALTITUDE Study of Aliskiren Terminated Early by Novartis
Larry Husten, PHD
Novartis announced today the early termination of the ALTITUDE trial, which was testing the effect of the direct renin inhibitor aliskiren (Tekturna, Rasilez) in patients with type 2 diabetes and renal impairment at high risk for cardiovascular and renal events. The action was based on the recommendation of the independent Data Monitoring Committee, after it found […]
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?